Amneal Pharmaceuticals, Inc. (AMRX) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Bridgewater, NJ, United States. Le PDG actuel est Chirag K. Patel.
AMRX a date d'introduction en bourse 2018-05-07, 8,300 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $4.13B.
Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products across multiple dosage forms and therapeutic areas. The company operates through three segments: Generics, which produces complex oral solids, injectables, ophthalmics, and other formulations; Specialty, which markets branded products for central nervous system disorders, endocrinology, and parasitic infections including brands like Rytary and Unithroid; and AvKARE, which supplies pharmaceuticals and medical products to government agencies and the Department of Defense. Amneal serves customers through wholesalers, distributors, hospitals, and retail pharmacies across the United States, India, Ireland, and internationally. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company has established itself as a significant player in both the generic and specialty pharmaceutical markets.
